Welcome to the POTP board, the DPP-IV company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: kenhott	5/16/2007 6:41:45 AM
	of 90

<reply> Here is the revised PR: CORRECTING and REPLACING Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study Tuesday May 15, 10:02 am ET BOSTON--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: POINT THERAPEUTICS ANNOUNCES INTERIM ANALYSIS TO BE PERFORMED ON ITS PHASE 3 TALABOSTAT WITH ALIMTA STUDY ADVERTISEMENT Point Therapeutics, Inc. (NASDAQ: POTP - News) today announced that the Company's Board of Directors approved an unscheduled interim analysis on the Phase 3 non-small cell lung cancer (NSCLC) study of talabostat in combination with pemetrexed (Alimta®: Eli Lilly). The study was designed to enroll 400 NSCLC patients who have already failed either one or two prior drug regimens. To date, approximately 360 patients have enrolled in the study. The interim analysis will examine approximately 150 events that have already been recorded in this study, with events being defined as either disease progression or death. The Company expects results from the interim analysis by the end of this month. "This analysis will produce the first clinical information on the effects of talabostat in a controlled, randomized trial," said Don Kiepert, President and CEO. "We felt that it was important to have controlled data at this time in order to properly assist us in our on going strategic and business initiatives." Talabostat's NSCLC program consists of two randomized, placebo-controlled, double-blind Phase 3 studies in the second-line and third-line setting. One of the Phase 3 studies is evaluating talabostat and pemetrexed versus placebo and pemetrexed. In the interim analysis, median progression-free survival (PFS) and overall survival data and the statistical analyses of these data for the talabostat treatment arm will be compared with the control arm by an independent data monitoring committee. The Company expects to report on the committee's recommendation to continue the trial or stop the trial either due to reaching statistical significance (p less than 0.005) or futility. The Company may also perform an unscheduled interim analysis on its Phase 3 study evaluating talabostat in combination with docetaxal (Taxotere® : sanofi-aventis), although a final decision has not been made. Originally the pemetrexed study was powered at 80% to detect an approximate hazard ratio of 1.4 (p=0.05) in PFS over the placebo arm with a positive trend in overall survival upon final analysis. The addition of the interim analysis has only slightly modified the final statistical plans. The trial remains powered at 80% to demonstrate an approximate hazard ratio of 1.4 in PFS with an adjusted statistical level of p=0.048. ======================== I don't think you can expect to get any information from the interim look other than a go or no go answer from the data monitoring board. Sorry.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next